Risk assessment for carnitine

Regulatory Toxicology and Pharmacology

Volumn 46, Issue 1, 2006, Pages 23-28

  Hathcock, John N ^a   Shao, Andrew ^a  

^a International and Scientific Affairs   (United States)

Author keywords

Carnitine; Observed safe level (OSL); Upper level of intake (UL)

Indexed keywords

CARNITINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; LEVACECARNINE; PLACEBO; PROPIONYLCARNITINE;

ACUTE HEART INFARCTION; ALZHEIMER DISEASE; APPETITE DISORDER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DIABETES MELLITUS; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; ENTEROPATHY; FLATULENCE; FRAGILE X SYNDROME; HUMAN; LOOSE FECES; MAJOR CLINICAL STUDY; NAUSEA; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PRURITUS; RETT SYNDROME; RISK ASSESSMENT; SIDE EFFECT; STOMACH PAIN; URINE ODOR;

CARNITINE; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; RISK ASSESSMENT; TOXICITY TESTS;

EID: 33747881144     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2006.06.007     Document Type: Article

References (45)

1. Commission on Life Sciences. National Research Council, 1983. Risk Assessment in the Federal Government: Managing the Process. National Academy Press, Washington, DC.
2. Expert Group on Vitamins and Minerals, 2003. Safe Upper Levels for Vitamins and Minerals. Food Standards Agency, United Kingdom.
3. FAO/WHO, 2006. A Model for Establishing Upper Levels of Intake for Nutrients and Related Substances. FAO/WHO Technical Workshop on Nutrient Risk Assessment, Geneva, Switzerland.
4. Food and Nutrition Board. Institute of Medicine, 1997. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. National Academy Press, Washington, DC.
5. Food and Nutrition Board. Institute of Medicine, 1998a. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin and Choline. National Academy Press, Washington, DC.
6. Food and Nutrition Board. Institute of Medicine, 1998b. Dietary Reference Intakes: A Risk Assessment Model for Establishing Upper Intake Levels for Nutrients. National Academy Press, Washington, DC.
7. Food and Nutrition Board. Institute of Medicine, 2000. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium and Carotenoids. National Academy Press, Washington, DC.
8. Food and Nutrition Board. Institute of Medicine, 2001. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium and Zinc. National Academy Press, Washington, DC.
9. National Toxicology Program, Department of Health and Human Services, 2005. Nominations to the Testing Program. Available from .
10. Scientific Committee on Food, 2001. Guidelines of the Scientific Committee on Food for the Development of Tolerable Upper Intake Levels for Vitamins and Minerals. European Commission, Brussels, Belgium.
11. Bain M.A., Fornasini G., and Evans A.M. Trimethylamine: metabolic, pharmacokinetic and safety aspects. Curr. Drug Metab. 6 (2005) 227-240
12. Bartels G.L., Remme W.J., den Hartog F.R., Wielenga R.P., and Kruijssen D.A. Additional antiischemic effects of long-term l-propionylcarnitine in anginal patients treated with conventional antianginal therapy. Cardiovasc. Drugs Ther. 9 (1995) 749-753
13. Benvenga S., Ruggeri R.M., Russo A., Lapa D., Campenni A., and Trimarchi F. Usefulness of l-carnitine, a naturally occurring peripheral antagonist of thyroid hormone action, in iatrogenic hyperthyroidism: a randomized, double-blind, placebo-controlled clinical trial. J. Clin. Endocrinol. Metab. 86 (2001) 3579-3594
14. Brevetti G., Diehm C., and Lambert D. European multicenter study on propionyl-l-carnitine in intermittent claudication. J. Am. Coll. Cardiol. 34 (1999) 1618-1624
15. Brevetti G., Perna S., Sabba C., Martone V.D., and Condorelli M. Propionyl-l-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. J. Am. Coll. Cardiol. 26 (1995) 1411-1416
16. Brevetti G., Perna S., Sabba C., Martone V.D., Di Iorio A., and Barletta G. Effect of propionyl-l-carnitine on quality of life in intermittent claudication. Am. J. Cardiol. 79 (1997) 777-780
17. Brooks III J.O., Yesavage J.A., Carta A., and Bravi D. Acetyl l-carnitine slows decline in younger patients with Alzheimer's disease: a reanalysis of a double-blind, placebo-controlled study using the trilinear approach. Int. Psychogeriatr. 10 (1998) 193-203
18. Cavallini G., Biagiotti G., Koverech A., and Vitali G. Oral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease. BJU Int. 89 (2002) 895-900
19. Dal Lago A., De Martini D., Flore R., Gaetani E., Gasbarrini A., Gerardino L., Pola R., Santoliquido A., Serricchio M., Tondi P., and Nolfe G. Effects of propionyl-l-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial. Drugs Exp. Clin. Res. 25 (1999) 29-36
20. De Grandis D., and Minardi C. Acetyl-l-carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long-term, randomised, double-blind, placebo-controlled study. Drugs R D. 3 (2002) 223-231
21. Derosa G., Cicero A.F., Gaddi A., Mugellini A., Ciccarelli L., and Fogari R. The effect of l-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. Clin. Ther. 25 (2003) 1429-1439
22. Ellaway C., Williams K., Leonard H., Higgins G., Wilcken B., and Christodoulou J. Rett syndrome: randomized controlled trial of l-carnitine. J. Child Neurol. 14 (1999) 162-167
23. Gurlek A., Tutar E., Akcil E., Dincer I., Erol C., Kocaturk P.A., and Oral D. The effects of l-carnitine treatment on left ventricular function and erythrocyte superoxide dismutase activity in patients with ischemic cardiomyopathy. Eur. J. Heart Fail. 2 (2000) 189-193
24. Hathcock J. Vitamin and Mineral Safety (2004), Council for Responsible Nutrition, Washington, DC
25. Higdon J. l-Carnitine. In: Hagen T.M. (Ed). The Linus Pauling Institute Micronutrient Information Center (Oregon State University) (2002), Linus Pauling Institute, Corvallis, OR
26. Iliceto S., Scrutinio D., Bruzzi P., D'Ambrosio G., Boni L., Di Biase M., Biasco G., Hugenholtz P.G., and Rizzon P. Effects of l-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the l-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial. J. Am. Coll. Cardiol. 26 (1995) 380-387
27. Iyer R., Gupta A., Khan A., Hiremath S., and Lokhandwala Y. Does left ventricular function improve with l-carnitine after acute myocardial infarction?. J. Postgrad. Med. 45 (1999) 38-41
28. Iyer R.N., Khan A.A., Gupta A., Vajifdar B.U., and Lokhandwala Y.Y. l-Carnitine moderately improves the exercise tolerance in chronic stable angina. J. Assoc. Physicians India 48 (2000) 1050-1052
29. Lenzi A., Sgro P., Salacone P., Paoli D., Gilio B., Lombardo F., Santulli M., Agarwal A., and Gandini L. A placebo-controlled double-blind randomized trial of the use of combined l-carnitine and l-acetyl-carnitine treatment in men with asthenozoospermia. Fertil. Steril. 81 (2004) 1578-1584
30. Loster H., Miehe K., Punzel M., Stiller O., Pankau H., and Schauer J. Prolonged oral l-carnitine substitution increases bicycle ergometer performance in patients with severe, ischemically induced cardiac insufficiency. Cardiovasc. Drugs Ther. 13 (1999) 537-546
31. Pistone G., Marino A., Leotta C., Dell'Arte S., Finocchiaro G., and Malaguarnera M. Levocarnitine administration in elderly subjects with rapid muscle fatigue: effect on body composition, lipid profile and fatigue. Drugs Aging 20 (2003) 761-767
32. Plioplys A.V., and Plioplys S. Amantadine and l-carnitine treatment of chronic fatigue syndrome. Neuropsychobiology 35 (1997) 16-23
33. Rebouche C.J. Carnitine function and requirements during the life cycle. FASEB J. 6 (1992) 3379-3386
34. Rebouche C.J. Renal handling of carnitine in experimental vitamin C deficiency. Metabolism 44 (1995) 1639-1643
35. Rebouche C.J. Kinetics, pharmacokinetics, and regulation of l-carnitine and acetyl-l-carnitine metabolism. Ann. N. Y. Acad. Sci. 1033 (2004) 30-41
36. Rubin M.R., Volek J.S., Gomez A.L., Ratamess N.A., French D.N., Sharman M.J., and Kraemer W.J. Safety measures of l-carnitine l-tartrate supplementation in healthy men. J. Strength Cond. Res. 15 (2001) 486-490
37. Ruud E., and Heiberg A. [New knowledge does not always make it simpler]. Tidsskr. Nor. Laegeforen. 124 (2004) 3256-3257
38. Siliprandi N., Di Lisa F., Menabo R., Ciman M., and Sartorelli L. Transport and functions of carnitine in muscles. J. Clin. Chem. Clin. Biochem. 28 (1990) 303-306
39. Singh R.B., Niaz M.A., Agarwal P., Beegum R., Rastogi S.S., and Sachan D.S. A randomised, double-blind, placebo-controlled trial of l-carnitine in suspected acute myocardial infarction. Postgrad. Med. J. 72 (1996) 45-50
40. Sorbi S., Forleo P., Fani C., and Piacentini S. Double-blind, crossover, placebo-controlled clinical trial with l-acetylcarnitine in patients with degenerative cerebellar ataxia. Clin. Neuropharmacol. 23 (2000) 114-118
41. Tomassini V., Pozzilli C., Onesti E., Pasqualetti P., Marinelli F., Pisani A., and Fieschi C. Comparison of the effects of acetyl l-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. J. Neurol. Sci. 218 (2004) 103-108
42. Torrioli M.G., Vernacotola S., Mariotti P., Bianchi E., Calvani M., De Gaetano A., Chiurazzi P., and Neri G. Double-blind, placebo-controlled study of l-acetylcarnitine for the treatment of hyperactive behavior in fragile X syndrome. Am. J. Med. Genet. 87 (1999) 366-368
43. Turpeinen A.K., Kuikka J.T., Vanninen E., Yang J., and Uusitupa M.I. Long-term effect of acetyl-l-carnitine on myocardial 123I-MIBG uptake in patients with diabetes. Clin. Auton. Res. 10 (2000) 13-16
44. Van Oudheusden L.J., and Scholte H.R. Efficacy of carnitine in the treatment of children with attention-deficit hyperactivity disorder. Prostaglandins Leukot. Essent. Fatty Acids 67 (2002) 33-38
45. Villani R.G., Gannon J., Self M., and Rich P.A. l-Carnitine supplementation combined with aerobic training does not promote weight loss in moderately obese women. Int. J. Sport Nutr. Exerc. Metab. 10 (2000) 199-207